The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Open accessAbstract
Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks) focal/grid laser treatment for diabetic macular edema (DME).Design Multicenter, randomized clinical trial.Participants Among participants from the trial with 3 years of follow-up who subsequently consented to a 2-year extension and survived through 5 years, 124 (97%) and 111 (92%) completed the 5-year visit in the prompt and deferred groups, respectively.Methods Random assignment to ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and prompt or deferred (≥24 weeks) focal/grid laser treatment.Main outcome measures Best-corrected visual acuity at the 5-year visit.Results The mean change in visual acuity letter score from baseline to the 5-year visit was +7.2 letters in the prompt laser group compared with +9.8 letters in the deferred laser group (mean difference, -2.6 letters; 95% confidence interval, -5.5 to +0.4 letters; P = 0.09). At the 5-year visit in the prompt versus deferred laser groups, there was vision loss of ≥10 letters in 9% versus 8%, an improvement of ≥10 letters in 46% versus 58%, and an improvement of ≥15 letters in 27% versus 38% of participants, respectively. From baseline to 5 years, 56% of participants in the deferred group did not receive laser. The median number of injections was 13 versus 17 in the prompt and deferral groups, including 54% and 45% receiving no injections during year 4 and 62% and 52% receiving no injections during year 5, respectively.Conclusions Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“where the majority of patients do not require treatment beyond 3 years.”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [35]
In the citing paper
“In Diabetic Retinopathy Clinical Research Network Protocol I clinical trial, a mean of 8 or 9 injections were given in Year 1, decreasing to 2 or 3 in Year 2, to 1 or 2 in Year 3, and to 0 or 1 in Year 4, depending on treatment assignment.35”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,431
Self-citationMitchell, P., Bandello, F. M., Schmidt-Erfurth, U. M., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,344
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 572
Self-citationIntravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
Elman, M. J., Qin, H., Aiello, L. P., Beck, R. W., Bressler, N. M., Ferris, F. L., Glassman, A. R., Maturi, R. K., & Melia, M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.022 · Cited by 322
Self-citationMixed models for longitudinal data
Cecílio‐Fernandes, D., Tio, R. A., & Jaarsma, D. A. D. C. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 118
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 105
Self-citationInference for the Marginal Model
(2009) · Springer series in statistics · doi:10.1007/978-1-4419-0300-6_6 · Cited by 6
Cited by
Sorted by citations
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,252
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A. J., Gardiner, T. A., Lyons, T. J., Hammes, H., Simó, R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,202
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,074
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S. S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Metadata
- Authors
- Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W.
- Affiliations
- Elman Retina Group (US)
- Jaeb Center for Health Research (US)
- Johns Hopkins University (US)
- Charlotte Eye Ear Nose & Throat Associates (US)
- Northwestern University (US)
- Retina Associates of Kentucky (US)
- Corresponding author
- Ayala, Allison
- ORCID
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 122
- Issue
- 2
- Pages
- 375-381
- ISSN
- 0161-6420 (ISSN-L)
- PMC
- PMC4520307
- OpenAlex
- W1980342089
- Cited by
- 562
- References
- 10
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 22 · 2023: 20 · 2022: 35 · 2021: 39 · 2020: 55 · 2019: 41 · 2018: 45 · 2017: 79 · 2016: 72 · 2015: 73
- FWCI
- 79.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (EY14231, EY-14229, EY18817, EY023207, U10EY018817, U10EY014229, U10EY023207, U10EY014231, UG1EY014231)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- diabetic macular edema, ranibizumab, intravitreal injection, best-corrected visual acuity, long-term visual outcomes, anti-VEGF therapy, vision loss, treatment duration extension, retinal laser treatment, anti-angiogenic therapy, treatment burden reduction
- MeSH terms
- Ranibizumab, Aged, Combined Modality Therapy, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Visual Acuity, Treatment Outcome, Laser Coagulation, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
